Cargando…

UK's MHRA publishes guidance for valproate PPP during pandemic

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	News Item
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272311/ http://dx.doi.org/10.1007/s40278-020-79292-y

Ejemplares similares

Advice on COVID-19 vaccines approved in UK by MHRA
Publicado: (2021)

Concerns raised with MHRA of anticoagulant use during pandemic
Publicado: (2020)

Valproate MHRA Guidance: Limitations and Opportunities
por: Watkins, Lance, et al.
Publicado: (2019)

MHRA COVID-19 website for reporting ADRs and incidents
Publicado: (2020)

MHRA Yellow Card reports on COVID-19 vaccine adverse reactions
Publicado: (2021)

Are We Following MHRA Guidance Regarding Valproate Prescription in Women of Child-Bearing Potential?
por: Shetty, Adarsh, et al.
Publicado: (2022)

COVID-19 pregnancy prevention guidance on teratogenic drugs
Publicado: (2020)

EMA guidance on risk management plans for COVID-19 vaccines reviewed
Publicado: (2020)

ICER publishes draft scoping report on COVID-19 treatments
Publicado: (2021)

NICE to publish guidelines for rare blood clotting syndrome from COVID-19 vaccination
Publicado: (2021)

Certain Emerade adrenaline auto-injector pens being recalled in UK
Publicado: (2020)

Serious cardiac AEs with hydroxychloroquine during COVID-19 pandemic
Publicado: (2020)

EMA: continue use of ACE inhibitors, sartans during COVID-19 pandemic
Publicado: (2020)

Evaluation of potential therapies for COVID-19 global pandemic
Publicado: (2020)

FDA remote evaluation of drug manufacturing during COVID-19
Publicado: (2021)

Updated infection prevention and control guidance published
Publicado: (2020)

Updated infection prevention and control guidance published
Publicado: (2020)

The MHRA pharmacovigilance inspection programme: priorities and challenges
por: Adams, Anna L, et al.
Publicado: (2019)

HTA assessment of COVID-19 interventions in Ireland
Publicado: (2020)

Remdesivir-related acute kidney injury in patients with COVID-19
Publicado: (2020)

EMA's CHMP meeting highlights from September 2020
Publicado: (2020)

TGA advises of potential taste disturbance with Andrographis paniculata
Publicado: (2020)

EMA issues recommendations on impurities in medicines
Publicado: (2020)

New potential interaction with emergency COVID-19 medicine remdesivir
Publicado: (2020)

Women disadvantaged by employment-based health financing
Publicado: (2020)

Codeine-containing medicines to be reclassified in NZ
Publicado: (2020)

Other adverse reaction research
Publicado: (2020)

Phase III trial of Covid-19 treatment paused for safety concerns
Publicado: (2020)

Other adverse reaction research
Publicado: (2020)

Non-serious case reports
Publicado: (2020)

EMA releases highlights from the CHMP's July meeting
Publicado: (2020)

Non-serious case reports
Publicado: (2020)

ISMP issues safety warnings for drug shortage replacement products
Publicado: (2020)

Risks of chloroquine or hydroxychloroquine use for COVID-19
Publicado: (2020)

Medsafe: potentially fatal adverse effects with Miracle Mineral Solution
Publicado: (2020)

Other adverse reaction research
Publicado: (2020)

Scottish Medicines Consortium September 2020 decisions
Publicado: (2020)

Antimalarial use in COVID-19 patients requires close monitoring
Publicado: (2020)

ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020)

Hydroxychloroquine: risk of QT prolongation and drug interactions
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gbc5rig7hgki1cd3vdu3oeqlgg